Samsung Bioepis seeks Europe approval for its Humira copy

SEOUL (Reuters) - Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news